by Sinette Goosen | Feb 12, 2018
The generic antiretroviral (ARV) market will be in a state of transition in 2018 with the introduction of a new fixed-dose combination (FDC) to serve as an alternative first-line treatment for adults. The product, known as “TLD,” is a single pill comprised of...
